Christine Gebski files SEC Form 4 disclosures for REPLIGEN CORP. They have made 5 open-market trades across 1 company since 2021, most recently 2024-05-14.
CIK 0001849585
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RGEN | 27,419 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2024-05-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RGEN | SELL | 2023-11-10 | 2023-11-13 | $147.13 | $1.1M | +5.7% | +14.3% | +34.4% |
| RGEN | SELL | 2022-08-04 | 2022-08-05 | $243.01 | $1.6M | +0.8% | -13.7% | -29.6% |
| RGEN | SELL | 2021-09-01 | 2021-09-02 | $285.33 | $1.9M | +3.0% | -5.1% | -3.8% |
| RGEN | SELL | 2021-05-14 | 2021-05-18 | $172.25 | $153K | +8.4% | +18.5% | +52.0% |
| RGEN | SELL | 2021-03-16 | 2021-03-18 | $196.88 | $276K | -6.5% | +4.8% | -6.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.